收费全文 | 3273篇 |
免费 | 191篇 |
2022年 | 10篇 |
2021年 | 21篇 |
2020年 | 15篇 |
2019年 | 8篇 |
2018年 | 14篇 |
2017年 | 19篇 |
2016年 | 55篇 |
2015年 | 72篇 |
2014年 | 105篇 |
2013年 | 151篇 |
2012年 | 172篇 |
2011年 | 193篇 |
2010年 | 127篇 |
2009年 | 131篇 |
2008年 | 205篇 |
2007年 | 227篇 |
2006年 | 199篇 |
2005年 | 205篇 |
2004年 | 203篇 |
2003年 | 210篇 |
2002年 | 215篇 |
2001年 | 44篇 |
2000年 | 36篇 |
1999年 | 53篇 |
1998年 | 73篇 |
1997年 | 59篇 |
1996年 | 41篇 |
1995年 | 49篇 |
1994年 | 42篇 |
1993年 | 39篇 |
1992年 | 46篇 |
1991年 | 26篇 |
1990年 | 27篇 |
1989年 | 21篇 |
1988年 | 29篇 |
1987年 | 20篇 |
1986年 | 21篇 |
1985年 | 27篇 |
1984年 | 29篇 |
1983年 | 23篇 |
1982年 | 30篇 |
1981年 | 19篇 |
1980年 | 18篇 |
1979年 | 12篇 |
1978年 | 18篇 |
1977年 | 20篇 |
1976年 | 20篇 |
1975年 | 16篇 |
1974年 | 10篇 |
1973年 | 14篇 |
Objectives
To assess the impact of a standardized pre-operative telephone checklist on the rate of late cancellations of ambulatory surgery (AMBUPROG trial).Design
Multicenter, two-arm, parallel-group, open-label randomized controlled trial.Setting
11 university hospital ambulatory surgery units in Paris, France.Participants
Patients scheduled for ambulatory surgery and able to be reached by telephone.Intervention
A 7-item checklist designed to prevent late cancellation, available in five languages and two versions (for children and adults), was administered between 7 and 3 days before the planned date of surgery, by an automated phone system or a research assistant. The control group received standard management alone.Main Outcome Measures
Rate of cancellation on the day of surgery or the day before.Results
The study population comprised 3900 patients enrolled between November 2012 and September 2013: 1950 patients were randomized to the checklist arm and 1950 patients to the control arm. The checklist was administered to 68.8% of patients in the intervention arm, 1002 by the automated phone system and 340 by a research assistant. The rate of late cancellation did not differ significantly between the checklist and control arms (109 (5.6%) vs. 113 (5.8%), adjusted odds ratio [95% confidence interval] = 0.91 [0.65–1.29], (p = 0.57)). Checklist administration revealed that 355 patients (28.0%) had not undergone tests ordered by the surgeon or anesthetist, and that 254 patients (20.0%) still had questions concerning the fasting state.Conclusions
A standardized pre-operative telephone checklist did not avoid late cancellations of ambulatory surgery but enabled us to identify several frequent causes.Trial Registration
ClinicalTrials.gov NCT01732159相似文献Background
Sleeping sickness (human African trypanosomiasis [HAT]) is caused by protozoan parasites and characterized by a chronic progressive course, which may last up to several years before death. We conducted two Phase 2 studies to determine the efficacy and safety of oral pafuramidine in African patients with first stage HAT.Methods
The Phase 2a study was an open-label, non-controlled, proof-of-concept study where 32 patients were treated with 100 mg of pafuramidine orally twice a day (BID) for 5 days at two trypanosomiasis reference centers (Angola and the Democratic Republic of the Congo [DRC]) between August 2001 and November 2004. The Phase 2b study compared pafuramidine in 41 patients versus standard pentamidine therapy in 40 patients. The Phase 2b study was open-label, parallel-group, controlled, randomized, and conducted at two sites in the DRC between April 2003 and February 2007. The Phase 2b study was then amended to add an open-label sequence (Phase 2b-2), where 30 patients received pafuramidine for 10 days. The primary efficacy endpoint was parasitologic cure at 24 hours (Phase 2a) or 3 months (Phase 2b) after treatment completion. The primary safety outcome was the rate of occurrence of World Health Organization Toxicity Scale Grade 3 or higher adverse events. All subjects provided written informed consent.Findings/Conclusion
Pafuramidine for the treatment of first stage HAT was comparable in efficacy to pentamidine after 10 days of dosing. The cure rates 3 months post-treatment were 79% in the 5-day pafuramidine, 100% in the 7-day pentamidine, and 93% in the 10-day pafuramidine groups. In Phase 2b, the percentage of patients with at least 1 treatment-emergent adverse event was notably higher after pentamidine treatment (93%) than pafuramidine treatment for 5 days (25%) and 10 days (57%). These results support continuation of the development program for pafuramidine into Phase 3. 相似文献Background
Sleeping sickness (human African trypanosomiasis [HAT]) is a neglected tropical disease with limited treatment options that currently require parenteral administration. In previous studies, orally administered pafuramidine was well tolerated in healthy patients (for up to 21 days) and stage 1 HAT patients (for up to 10 days), and demonstrated efficacy comparable to pentamidine.Methods
This was a Phase 3, multi-center, randomized, open-label, parallel-group, active control study where 273 male and female patients with first stage Trypanosoma brucei gambiense HAT were treated at six sites: one trypanosomiasis reference center in Angola, one hospital in South Sudan, and four hospitals in the Democratic Republic of the Congo between August 2005 and September 2009 to support the registration of pafuramidine for treatment of first stage HAT in collaboration with the United States Food and Drug Administration. Patients were treated with either 100 mg of pafuramidine orally twice a day for 10 days or 4 mg/kg pentamidine intramuscularly once daily for 7 days to assess the efficacy and safety of pafuramidine versus pentamidine. Pregnant and lactating women as well as adolescents were included.The primary efficacy endpoint was the combined rate of clinical and parasitological cure at 12 months. The primary safety outcome was the frequency and severity of adverse events. The study was registered on the International Clinical Trials Registry Platform at www.clinicaltrials.gov with the number ISRCTN85534673.Findings/Conclusions
The overall cure rate at 12 months was 89% in the pafuramidine group and 95% in the pentamidine group; pafuramidine was non-inferior to pentamidine as the upper bound of the 95% confidence interval did not exceed 15%. The safety profile of pafuramidine was superior to pentamidine; however, 3 patients in the pafuramidine group had glomerulonephritis or nephropathy approximately 8 weeks post-treatment. Two of these events were judged as possibly related to pafuramidine. Despite good tolerability observed in preceding studies, the development program for pafuramidine was discontinued due to delayed post-treatment toxicity. 相似文献During the fallow period, non-legume cover crop species can capture mineral nitrogen (N) and thus decrease nitrate leaching, whereas legume cover crop species can provide a green manuring service that increases N availability for the subsequent crop. The aim of our study was to investigate the ability of bispecific mixtures to simultaneously produce these two services of N management in relation to their interspecific interactions.
MethodsThree field experiments were conducted at contrasting sites from summer to autumn to evaluate 25 mixtures and 10 sole crops. We measured biomass, N acquisition, C:N ratio and soil mineral N. Ecosystem services were assessed using both experimental data and simulation model predictions.
ResultsOverall, prediction of N mineralized from cover crop residues was significantly higher for mixtures than for non-legume sole crops. Predictions of nitrate leached after mixtures did not differ significantly from those after non-legume sole crops and remained significantly lower than those under bare soil, especially for mixtures with turnip rape which benefitted greatly from being in mixtures.
ConclusionsSome of the mixtures provided a choice of compromises between the two ecosystem services, which helps define solutions for adapting mixture choice according to the site’s soil and climate characteristics and to fallow period management.
相似文献